Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Merrimack Pharmaceuticals has initiated the dosing of first patient in a Phase 1 clinical trial of MM-151, indicated to treat patients with refractory advanced solid tumors.
Subscribe to our email newsletter
MM-151 is an oligoclonal therapeutic consisting of a mixture of three fully human monoclonal antibodies designed to bind to non-overlapping epitopes of the epidermal growth factor receptor (EGFR).
The company said MM-151 is Merrimack’s fifth program to enter clinical development.
The trial is intended to evaluate the safety of MM-151 and determine the recommended Phase 2 dose.
The first patient was enrolled at the Indiana University Health Arnett and Horizon Oncology clinical site and four sites are expected to participate in this trial.